OSI Pharma reiterated by Bear Stearns at outperform

OSI Pharmaceuticals Inc. was maintained by Bear Stearns analyst Akhtar Samad at an outperform rating with a price target on the stock of $65 per share, acknowledging concerns about the lung cancer drug Tarceva being expanded for use in pancreatic cancer. Bear Stearns noted it had seen Tarceva's use for pancreatic cancer only as a modest sales opportunity. OSI Pharma shares Tuesday were up $1.41, or 4.59%, at $32.15 on volume of 5,269,439 shares versus the three-month running average of 2,139,490 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.